Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies

Table 2

Extraction recovery and matrix effect of brigatinib and brigatinib-analog in rat plasma and brain homogenate (mean ± SD, n = 3).

Analytes	Matrix	Spiked conc. (ng/mL)	Extraction recovery (%)		Matrix effect (%)
			Mean ± SD	RSD	Mean ± SD	RSD
Brigatinib	Plasma	2.0	102.37 ± 9.23	9.02	92.80 ± 11.08	11.94
		400	97.61 ± 5.55	5.69	98.62 ± 7.10	7.19
		1600	93.10 ± 4.46	4.79	102.97 ± 8.82	8.57
	Brain homogenate	1.0	88.28 ± 5.13	5.81	93.78 ± 9.43	10.06
		200	86.81 ± 4.83	5.56	95.56 ± 8.47	8.86
		800	89.74 ± 4.50	5.01	96.62 ± 8.12	8.40
Brigatinib-analog	Plasma	2.0	112.68 ± 10.89	9.66	97.89 ± 12.09	12.35
		400	106.42 ± 5.32	4.99	95.99 ± 6.41	6.68
		1600	108.24 ± 7.72	7.13	95.94 ± 8.58	8.94
	Brain homogenate	1.0	97.43 ± 7.03	7.22	97.68 ± 7.50	7.68
		200	91.66 ± 5.43	5.92	102.14 ± 3.52	3.45
		800	98.65 ± 8.66	8.78	94.06 ± 6.15	6.54